This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the potential of RP1 in combination with Libtayo in patients with Cutaneous squamous cell carcinoma (CSCC)

Ticker(s): REPL, REGN

Who's the expert?

Institution: Moffitt

  • Senior member, chief academic officer, director of regional therapies, cutaneous oncology department at Moffitt's cancer center
  • Professor of Surgery at the University of South Florida, Morsani School of Medicine.
  • Research and clinical interests include the regional therapy treatment of cutaneous melanoma and non-melanoma skin cancers, soft tissue sarcomas. 

Interview Goal
Talk about current treatment in Cutaneous squamous cell carcinoma (CSCC) and potential of improvement with addition of RP1.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.